23.10.2014 • NewsEU CommissionDuPontHoneywell

EU Commission Steps up Refrigerants Probe

The EU Commission is stepping up its investigation of US chemical giants DuPont and Honeywell's business practices in developing automotive refrigerants.

Begun in 2011, the probe was ramped up a notch this week as the Commission sent the companies a formal statement of objections. It said the investigation panel's "preliminary view" was that the DuPont-Honeywell cooperative agreement begun in 2010 to produce the refrigerant HFO-1234yf may have limited availability and technical development of the product.

The partnership was established in reaction to the EU's adoption of new environmental standards for refrigerants in 2006, set down in the Mobile Air Conditioning (MAC) directive.

In filing its initial announcement of the antitrust probe, the Commission said it had received complaints from other companies that the two US players were preventing them from developing products with low global warming potential.

Both companies reacted to the Commission's announcements with statements of their own.

Thierry F.J. Vanlancker, president of DuPont Chemicals & Fluoroproducts, said his company will "vigorously defend" itself against the Commission's "allegations and preliminary conditions," arguing that it has "no basis in law or fact."

Without the cooperation, HFO-1234yf would not have been successfully developed and brought to market and there would today be no commercially available solution satisfying the MAC Directive's criteria, Vanlancker added.

In a separate statement, Honeywell said the Commission's objections were "baseless" and conflict with the EU's own laws encouraging collaboration on development.

EU rules permit companies to respond to the Commission's objections and request a hearing to present their arguments.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.